Healthcare companies by risk reading
Healthcare companies by risk reading: 1,695 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 21 October 2026.
Composite readings for 14,899 companies, recomputed 21 October 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| OUE Healthcare Limited 5WA.SI | 43 | Elevated | Healthcare | Singapore | 5 / 6 | $170M |
| BICO Group AB BICO | 45 | Elevated | Healthcare | Sweden | 4 / 6 | $170M |
| Scancell Hldgs Plc SCLP | 72 | Stretched | Healthcare | United Kingdom | 4 / 6 | $169M |
| Oramed Pharmaceuticals Inc ORMP | 64 | Stretched | Healthcare | United States | 4 / 6 | $168M |
| Paragon Care Limited PGC.AX | 76 | Stretched | Healthcare | Australia | 3 / 6 | $168M |
| JBM (Healthcare) Limited 2161.HK | 18 | Contained | Healthcare | Hong Kong | 5 / 6 | $167M |
| Trinity Biotech Plc TRIB | 82 | Acute | Healthcare | Ireland | 4 / 6 | $166M |
| Pacific Edge Limited PEB.AX | 67 | Stretched | Healthcare | New Zealand | 4 / 6 | $165M |
| OptimizeRx Corp OPRX | 29 | Normal | Healthcare | United States | 4 / 6 | $165M |
| PW Medtech Group Limited 1358.HK | 32 | Normal | Healthcare | China | 5 / 6 | $164M |
| MediWound Ltd MDWD | 81 | Acute | Healthcare | Israel | 5 / 6 | $164M |
| Precision Biosciences Inc DTIL | 64 | Stretched | Healthcare | United States | 6 / 6 | $164M |
| Centrale dAchat Française pour lOutre-Mer Société Anonyme ALCGM | 34 | Normal | Healthcare | France | 5 / 6 | $163M |
| CAMP4 Therapeutics Corp CAMP | 61 | Stretched | Healthcare | United States | 5 / 6 | $163M |
| Quipt Home Medical Corp QIPT | 32 | Normal | Healthcare | United States | 5 / 6 | $162M |
| Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. 2566.HK | 36 | Normal | Healthcare | China | 5 / 6 | $159M |
| Aoxin Q & M Dental Group Limited 1D4.SI | 31 | Normal | Healthcare | Singapore | 5 / 6 | $159M |
| Upstream Bio Inc UPB | 56 | Elevated | Healthcare | United States | 5 / 6 | $153M |
| EDAP TMS S.A. FOCL | 68 | Stretched | Healthcare | France | 6 / 6 | $153M |
| Assertio Holdings Inc ASRT | 69 | Stretched | Healthcare | United States | 3 / 6 | $151M |
| Kanamic Network Co.,LTD 3939.T | 13 | Contained | Healthcare | Japan | 5 / 6 | $151M |
| SEED Co.,Ltd. 7743.T | 41 | Elevated | Healthcare | Japan | 5 / 6 | $150M |
| Essex Bio-Technology Limited 1061.HK | 26 | Normal | Healthcare | China | 5 / 6 | $150M |
| Bastide Le Confort Médical SA BLC | 40 | Elevated | Healthcare | France | 5 / 6 | $150M |
| Coherus Biosciences Inc CHRS | 68 | Stretched | Healthcare | United States | 6 / 6 | $148M |
| Zhaoke Ophthalmology Limited 6622.HK | 68 | Stretched | Healthcare | China | 5 / 6 | $146M |
| Athens Medical C.S.A. IATR | 53 | Elevated | Healthcare | Greece | 5 / 6 | $146M |
| Neuronetics Inc STIM | 53 | Elevated | Healthcare | United States | 5 / 6 | $146M |
| Entera Bio Ltd ENTX | 66 | Stretched | Healthcare | Israel | 4 / 6 | $145M |
| JW (Cayman) Therapeutics Co. Ltd JNY | 43 | Elevated | Healthcare | China | 5 / 6 | $145M |
| Fangzhou Inc. 6086.HK | 24 | Normal | Healthcare | China | 5 / 6 | $145M |
| Mayne Pharma Group Limited MYX.AX | 31 | Normal | Healthcare | Australia | 3 / 6 | $144M |
| Anbio Biotechnology - Class A NNNN | 49 | Elevated | Healthcare | Germany | 4 / 6 | $144M |
| Empro Group Inc EMPG | 31 | Normal | Healthcare | Malaysia | 5 / 6 | $143M |
| Journey Medical Corp DERM | 57 | Elevated | Healthcare | United States | 4 / 6 | $143M |
| PHOTOCURE PHO.OL | 38 | Normal | Healthcare | Norway | 3 / 6 | $142M |
| FINDEX Inc. 3649.T | 20 | Normal | Healthcare | Japan | 4 / 6 | $141M |
| EKF Diagnostics Holdings Plc EKF | 30 | Normal | Healthcare | United Kingdom | 5 / 6 | $141M |
| KORU Medical Systems Inc KRMD | 51 | Elevated | Healthcare | United States | 6 / 6 | $139M |
| PW MEDTECH GROUP DL-0001 PWE | 35 | Normal | Healthcare | China | 5 / 6 | $139M |
| JW (Cayman) Therapeutics Co. Ltd 2126.HK | 43 | Elevated | Healthcare | China | 5 / 6 | $139M |
| Town Health International Medical Group Limited 3886.HK | 32 | Normal | Healthcare | Hong Kong | 5 / 6 | $139M |
| Viromed Medical AG VME.DE | 28 | Normal | Healthcare | Germany | 3 / 6 | $138M |
| MaxCyte Inc MXCT | 53 | Elevated | Healthcare | United States | 6 / 6 | $138M |
| Innate Pharma IPHA | 77 | Stretched | Healthcare | France | 5 / 6 | $137M |
| Yonghe Medical Group Co., Ltd. 2279.HK | 25 | Normal | Healthcare | China | 5 / 6 | $135M |
| Inspecs Group plc SPEC | 47 | Elevated | Healthcare | United Kingdom | 4 / 6 | $135M |
| Dingdang Health Technology Group Ltd. 9886.HK | 48 | Elevated | Healthcare | China | 5 / 6 | $134M |
| Saniona AB SANION | 11 | Contained | Healthcare | Denmark | 4 / 6 | $134M |
| OrganiGram Holdings Inc OGI | 36 | Normal | Healthcare | Canada | 5 / 6 | $133M |
| CUC Inc. 9158.T | 32 | Normal | Healthcare | Japan | 5 / 6 | $132M |
| Organogenesis Holdings Inc - Class A ORGO | 42 | Elevated | Healthcare | United States | 5 / 6 | $131M |
| Korro Bio Inc KRRO | 75 | Stretched | Healthcare | United States | 4 / 6 | $131M |
| Quanterix Corp QTRX | 59 | Elevated | Healthcare | United States | 6 / 6 | $131M |
| Avidity Biosciences Inc RNA | 48 | Elevated | Healthcare | United States | 5 / 6 | $130M |
| Hyloris Developmentsen Sa HYL | 53 | Elevated | Healthcare | Belgium | 5 / 6 | $130M |
| Freenome, Inc. FRNM | 57 | Elevated | Healthcare | United States | 5 / 6 | $130M |
| DXS International PLC DXSP.AQ | 27 | Normal | Healthcare | United Kingdom | 3 / 6 | $128M |
| Health Catalyst Inc HCAT | 85 | Acute | Healthcare | United States | 4 / 6 | $128M |
| WW International Inc WW | 60 | Stretched | Healthcare | United States | 5 / 6 | $127M |
| Orthocell Limited OCC.AX | 41 | Elevated | Healthcare | Australia | 4 / 6 | $127M |
| Pharma Foods International Co., Ltd. 2929.T | 32 | Normal | Healthcare | Japan | 5 / 6 | $127M |
| Vytrus Biotech S.A. VYT | 10 | Contained | Healthcare | Spain | 5 / 6 | $127M |
| Voyager Therapeutics Inc VYGR | 63 | Stretched | Healthcare | United States | 5 / 6 | $126M |
| ARRAIL GROUP LTD. I1D | 40 | Elevated | Healthcare | China | 5 / 6 | $125M |
| Aroa Biosurgery Limited ARX.AX | 31 | Normal | Healthcare | New Zealand | 4 / 6 | $125M |
| Sipai Health Technology Co., Ltd. 0314.HK | 57 | Elevated | Healthcare | China | 5 / 6 | $124M |
| OLBA DVx HEALTHCARE, Inc. 2689.T | 29 | Normal | Healthcare | Japan | 4 / 6 | $124M |
| CANbridge Pharmaceuticals Inc. 1228.HK | 56 | Elevated | Healthcare | China | 5 / 6 | $123M |
| Bioventix BVXP | 36 | Normal | Healthcare | United Kingdom | 4 / 6 | $121M |
| Codexis Inc CDXS | 67 | Stretched | Healthcare | United States | 6 / 6 | $121M |
| Fonar Corp FONR | 34 | Normal | Healthcare | United States | 4 / 6 | $120M |
| Owlet Inc - Class A OWLT | 54 | Elevated | Healthcare | United States | 6 / 6 | $120M |
| VSee Health Inc VSEE | 62 | Stretched | Healthcare | United States | 3 / 6 | $117M |
| CURATIS N AG CURN | 56 | Elevated | Healthcare | Switzerland | 4 / 6 | $117M |
| Definitive Healthcare Corp - Class A DH | 82 | Acute | Healthcare | United States | 5 / 6 | $117M |
| C-MER Medical Holdings Limited 3309.HK | 30 | Normal | Healthcare | Hong Kong | 5 / 6 | $117M |
| 4BASEBIO PLC EO 1 88Q | 41 | Elevated | Healthcare | United Kingdom | 5 / 6 | $116M |
| 4BASEBIO UK SOCIETAS 4BB | 41 | Elevated | Healthcare | United Kingdom | 5 / 6 | $116M |
| Fuso Pharmaceutical Industries,Ltd. 4538.T | 44 | Elevated | Healthcare | Japan | 5 / 6 | $115M |
| Kindstar Globalgene Technology, Inc. 9960.HK | 59 | Elevated | Healthcare | China | 5 / 6 | $115M |
| Meihua International Medical Technologies Co Ltd - Class A MHUA | 44 | Elevated | Healthcare | China | 5 / 6 | $115M |
| 26U 26U | 55 | Elevated | Healthcare | Switzerland | 4 / 6 | $114M |
| NRX Pharmaceuticals Inc NRXP | 67 | Stretched | Healthcare | United States | 3 / 6 | $114M |
| FARMINVESTE MLFMV.LS | 45 | Elevated | Healthcare | Portugal | 4 / 6 | $113M |
| BenQ BM Holding Cayman Corp. 2581.HK | 37 | Normal | Healthcare | China | 5 / 6 | $113M |
| Seer Inc - Class A SEER | 38 | Normal | Healthcare | United States | 6 / 6 | $112M |
| Pyxis Oncology Inc PYXS | 76 | Stretched | Healthcare | United States | 4 / 6 | $112M |
| Humacyte Inc HUMA | 69 | Stretched | Healthcare | United States | 4 / 6 | $111M |
| Genelux Corp GNLX | 69 | Stretched | Healthcare | United States | 5 / 6 | $111M |
| C-Rad AB (publ) CRAD-B | 27 | Normal | Healthcare | Sweden | 4 / 6 | $110M |
| Beijing Airdoc Technology Co., Ltd. 2251.HK | 45 | Elevated | Healthcare | China | 5 / 6 | $110M |
| Foghorn Therapeutics Inc FHTX | 41 | Elevated | Healthcare | United States | 5 / 6 | $110M |
| Vita Life Sciences Ltd VLS | 22 | Normal | Healthcare | Australia | 4 / 6 | $109M |
| Satudora Holdings Co.,Ltd. 3544.T | 41 | Elevated | Healthcare | Japan | 5 / 6 | $109M |
| Sisram Medical Ltd 1696.HK | 47 | Elevated | Healthcare | Israel | 5 / 6 | $109M |
| Burning Rock Biotech Ltd BNR | 47 | Elevated | Healthcare | China | 5 / 6 | $108M |
| Adagene Inc ADAG | 56 | Elevated | Healthcare | China | 5 / 6 | $108M |
| Medexus Pharmaceuticals Inc MDP | 32 | Normal | Healthcare | Canada | 5 / 6 | $108M |
| LifeMD Inc LFMD | 45 | Elevated | Healthcare | United States | 4 / 6 | $108M |
By sector
Industrials 3,117Technology 2,425Consumer Cyclical 2,231Healthcare 1,695Consumer Defensive 1,055Basic Materials 1,055Real Estate 1,011Communication Services 956Energy 487Utilities 343Financial Services 90
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.